Tools like AlphaFold and RFdiffusion have revolutionized the speed of protein design, allowing scientists to generate thousands of sequences in days. This surge in digital candidates often creates a bottleneck in the lab, where traditional, sequential testing methods fail to keep pace with computational output. Tsingke’s new integrated workflow addresses this by breaking the validation process into two distinct, scalable stages.

The initial phase utilizes batch gene synthesis and parallel expression to rapidly generate and screen large candidate sets using ELISA-based binding assays. Once promising molecules are identified, the process shifts to a secondary stage involving scale-up production and purification. Advanced quantitative analysis, including BLI and SPR technologies, provides kinetic parameters such as KD, kon, and koff to ensure only the most viable candidates proceed.

Supporting this throughput is a robust technical infrastructure capable of processing up to 1,500 candidates daily. Tsingke provides gene-to-antibody delivery in as little as seven days, handling complex sequences such as high GC content and tandem repeats. By leveraging mammalian cell-based and cell-free expression platforms, the company provides researchers with the flexibility to adapt experimental strategies across diverse project stages and protein formats, from scFv to full-length IgG.